Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.35 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.35 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.35 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.35 |
| ▸ | ALB | P02768 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | RARB | P10826 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14975818 | 0.86 | SLC7A5 (0.45) | SLC7A5LMNAKMT2ALOXL2NR1H2 | |
| SCHEMBL5239448 | 0.83 | LMNA (0.42) | SLC7A5LMNAKMT2ANR1H2KDM4E | |
| SCHEMBL855255 | 0.81 | LOXL2 (0.41) | SLC7A5LMNAKMT2ALOXL2NR1H2 | |
| SCHEMBL11250163 | 0.81 | KMT2A (0.43) | LMNAKMT2ASRCESR1BLM | |
| SCHEMBL28064960 | 0.80 | SRC (0.57) | LMNAKMT2ASRCCYP2D6 | |
| SCHEMBL3335866 | 0.80 | SRC (0.57) | LMNAKMT2ASRCCYP2D6 | |
| SCHEMBL5983603 | 0.80 | SRC (0.57) | LMNAKMT2ASRCCYP2D6 | |
| Ammonia Solution, Strong SCHEMBL23885016 | 0.80 | LOXL2 (0.40) | SLC7A5LMNAKMT2ALOXL2NR1H2 | |
| SCHEMBL28216971 | 0.80 | SRC (0.54) | LMNALOXL2KDM4ESMN1; SMN2BACE1 | |
| SCHEMBL1818550 | 0.79 | SLC7A5 (0.53) | SLC7A5LMNAKMT2AKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250170253-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE INC (US) | 2025-05-29 | — | — | US | disclosed |
| US-20220265841-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE, INC. | 2022-08-25 | — | — | US | disclosed |
| EP-3875082-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | Endocyte, Inc. (US) | 2021-09-08 | — | — | EP | disclosed |
| EP-3858341-A1 | PSMA LIGAND-CONTAINING CONJUGATES FOR THE TREATMENT OF PROSTATE CANCER | Endocyte, Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| US-20210154312-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE, INC. | 2021-05-27 | — | — | US | disclosed |
| US-20210154311-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE INC (US) | 2021-05-27 | — | — | US | disclosed |
| US-10912840-B2 | Conjugates for treating diseases caused by PSMA expressing cells | ENDOCYTE, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-20190314515-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE, INC. | 2019-10-17 | — | — | US | disclosed |
| US-20180289826-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE INC (US) | 2018-10-11 | — | — | US | disclosed |
| US-20180271991-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE INC (US) | 2018-09-27 | — | — | US | disclosed |
| US-20170258932-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE INC (US) | 2017-09-14 | — | — | US | disclosed |
| US-9636413-B2 | Conjugates for treating diseases caused by PSMA expressing cells | ENDOCYTE, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-20160361376-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE, INC. | 2016-12-15 | — | — | US | disclosed |
| US-20160361432-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE INC (IN) | 2016-12-15 | — | — | US | disclosed |
| US-20160361433-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE INC (US) | 2016-12-15 | — | — | US | disclosed |
| US-20150297735-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE, INC. | 2015-10-22 | — | — | US | disclosed |
| EP-2919774-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | Endocyte, Inc. (US) | 2015-09-23 | — | — | EP | disclosed |
| CN-104797247-A | Conjugates for treating diseases caused by PSMA-expressing cells | ENDOCYTE INC | 2015-07-22 | — | — | CN | disclosed |
| WO-2014078484-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE, INC. (US) | 2014-05-22 | — | — | WO | disclosed |
| WO-2001027096-A9 | AMINOMETHYL-(HETERO)ARYL DERIVATIVES AND THEIR USE AS TRYPTASE INHIBITORS | PROTHERICS MOLECULAR DESIGN LT (GB) | 2001-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160361376-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | SLC7A5 1698/4885LMNA 3596/4885KMT2A 961/4885 |
| US-20210154311-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | SLC7A5 1698/4885LMNA 3596/4885KMT2A 961/4885 |
| US-20210154312-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | SLC7A5 1698/4885LMNA 3596/4885KMT2A 961/4885 |
| US-20160361432-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | SLC7A5 1698/4885LMNA 3596/4885KMT2A 961/4885 |
| US-20220265841-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | SLC7A5 1698/4885LMNA 3596/4885KMT2A 961/4885 |
| US-20250170253-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | SLC7A5 1698/4885LMNA 3596/4885KMT2A 961/4885 |
| US-20180271991-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | SLC7A5 1698/4885LMNA 3596/4885KMT2A 961/4885 |
| US-20190314515-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | SLC7A5 1698/4885LMNA 3596/4885KMT2A 961/4885 |
| US-20160361433-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | SLC7A5 1698/4885LMNA 3596/4885KMT2A 961/4885 |
| US-20170258932-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | SLC7A5 1698/4885LMNA 3596/4885KMT2A 961/4885 |
| US-10912840-B2 | Conjugates for treating diseases caused by PSMA expressing cells | FOLH1, KLK3, CD47 | SLC7A5 1698/4885LMNA 3596/4885KMT2A 961/4885 |
| US-20180289826-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | SLC7A5 1698/4885LMNA 3596/4885KMT2A 961/4885 |
| US-20150297735-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | SLC7A5 1698/4885LMNA 3596/4885KMT2A 961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.